Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 14, 2019

Tolero doses first patient in Phase I TP-1287 trial

Tolero Pharmaceuticals has dosed the first patient in a Phase I trial assessing TP-1287 for the treatment of patients with advanced solid tumours.

Tolero Pharmaceuticals has dosed the first patient in a Phase I trial assessing TP-1287 for the treatment of patients with advanced solid tumours.

The Phase l trial is currently taking place at sites in the US and intends to investigate the maximum tolerated dose and dose-limiting toxicities of TP-1287.

Tolero intends to enrol 60 patients as part of the open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamics trial.

Patients with advanced metastatic or progressive solid tumours who are refractory to, or intolerant of will be eligible for the trial.

“The initiation of this study is an important step forward in understanding the potential of TP-1287.”

The trial’s primary endpoints are to establish the maximum tolerated dose and dose-limiting toxicities of oral TP-1287, as well as determine the Recommended Phase II Dose (RP2D).

Secondary endpoints comprise pharmacokinetics, antitumour activity, and pharmacodynamics of TP-1287.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The study is set to be completed in May 2021 and primary data is expected to be available by February 2021.

Tolero Pharmaceuticals CEO David Bearss said: “The initiation of this study is an important step forward in understanding the potential of TP-1287 in patients with solid tumours.

“We believe that the oral administration of TP-1287 may be beneficial in disease settings where this form of administration is preferred or when used in combination with other targeted agents.”

TP-1287 is an experimental oral cyclin-dependent kinase 9 (CDK9) inhibitor that showed positive oral bioavailability in preclinical models.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU